Rapid diagnosis of infections

Day Zero Diagnostics Appoints Gail Marcus to its Board

November 9 2022

Day Zero Diagnostics appoints Gail Marcus to its Board of Directors as an independent director.

Day Zero Diagnostics raises $8.2M from CARB-X

October 24 2022

Day Zero Diagnostics receives an $8.2 million award in optional stage funding from CARB-X.

Day Zero receives $8.2M to speed development of infectious disease diagnostic

October 21 2022

Day Zero receives $8.2M from CARB-X to speed development of infectious disease diagnostics.

Day Zero Diagnostics secures additional $8.2M from CARB-X

October 20 2022

Additional CARB-X funding supports the transition into product development of the firm's whole-genome sequencing and machine learning-based approach to antimicrobial resistance profiling.

Day Zero Diagnostics at EADA 2021: A better way to diagnose and treat sepsis is on the horizon

January 5 2022

Learn how we are predicting antimicrobial susceptibility directly from blood using whole-genome sequencing with Day Zero Diagnostic's Scientific Co-founder, Melis Anahtar, MD, Phd.

Diagnosis On Day Zero

January 4 2022

Day Zero Diagnostics was featured in AACC's December issue of "Clinical Laboratory News", highlighting our work around whole genome sequencing and machine learning for rapid diagnosis of infections directly from blood.